SYNAGEVA BIOPHARMA CORP — Net Income by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1b0e47ec-98b7-4382-b2fe-8b04dcba2616/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2014 | $-192.6M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-065709 |
| FY 2013 | $-95.5M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-080123 |
| FY 2012 | $-42.9M | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-106244 |
| FY 2011 | $-25.3M | 2011-01-01 – 2011-12-31 | evidence 0001193125-13-106244 |
| FY 2010 | $-10.8M | 2010-01-01 – 2010-12-31 | evidence 0001193125-13-106244 |
| FY 2009 | $-11.4M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-127552 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
SYNAGEVA BIOPHARMA CORP — all facts · Revenue · Operating Income